Overview of Dr. Shreenivas
I am a medical oncologist with a clinical practice in gastrointestinal and rare cancers. From a research standpoint, I am primarily affiliated with City of Hope 's early drug development program. Our group believes in the concept of vertical research, and the overall thrust of my research work has been focused on creating a small but significant impact in a few areas of oncology. They are as follows: 1) improve our understanding of radiation and immunotherapy resistance patterns and develop clinical trial concepts of novel multimodal therapeutic approaches in head& neck and gastrointestinal cancers. 2) develop pilot projects to better understand the role of tumor-informed circulating tumor DNA assays in response assessments. 3) utilization of individualized and personalized molecular-based therapies for the management of rare cancers, and finally 4) survivorship care and symptom management.
Office
1500 E. Duarte Road
Duarte, CA 91010
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2015 - 2018
- BronxCare Health SystemResidency, Internal Medicine, 2012 - 2015
- JSS Medical College MysoreClass of 2010
- Icahn school of medicine Newyork MSCR, Clinical research
Certifications & Licensure
- CA State Medical License 2024 - 2026
- WI State Medical License 2018 - 2025
- NY State Medical License 2015 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Successful Targeting of SomaticAlterations With Belzutifan in Two Cases.Bicky Thapa, Aditya Shreenivas, Kathryn Bylow, Hui-Zi Chen, Ben George
Journal of Immunotherapy and Precision Oncology. 2024-11-01 - Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy.Sewanti Limaye, Mohan Menon, Shambhavi Singh, Pritam Kataria, Aditya V Shreenivas
Journal of Immunotherapy and Precision Oncology. 2024-08-01 - Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.Nabil F Saba, Stuart J Wong, Tahseen Nasti, Ashley Alesia McCook-Veal, Mark W McDonald
JAMA Oncology. 2024-07-01
Press Mentions
- Their cancers can't be cured. But new treatments are increasing the length, and quality, of their lives.June 13th, 2024
- Keeping Ahead of Oncology Advances Requires VigilanceSeptember 11th, 2018
Grant Support
- Cancer Center Pilot GrantMedical College of WisconsinPresent
- NRG NCORP GrantNRGPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: